Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cybin Inc

HELP ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$13.63

▼ -2.54%

Market Cap $1.00B · Vol 286.82K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.00B

Small Cap

Div Yield

N/A

EPS Growth

+34.31%

YoY

RSI (14)

67.19

Momentum

Beta

0.66

vs Market

52W High

$14.33

4.88% below

52W Low

$3.77

262.02% above

Volume

286.82K

Avg 473.30K

P/B

1.50

Price-to-book

ROE

-91.89%

Return on equity

Free Float

81.77%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Cybin Inc (HELP) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does HELP pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+15.70%

+78.87%

+207.67%

+75.64%

YTD

+66.63%

+82.95%

+19.56%

-83.99%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-106,366,250.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-91.89%
ROA · ROIC	-68.67% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.50
P/FCF	N/A
EPS Growth	+34.31%
Outstanding Shares	73.06M

Technical Indicators

50-Day SMA	$8.33
200-Day SMA	$6.54
RSI (14)	67.19
Beta	0.66
52-Week High	$14.33
52-Week Low	$3.77

Volume Today	286.82K
Avg Daily Volume (30D)	473.30K
Relative Volume	0.61x
Volatility (10D)	52.17
Volatility (30D)	94.13
Free Float	81.77%

Analyst Consensus

BUY

Current Price $13.63

Mean Target $41.22

52W Low$3.77 52W High$14.33

Current

Target

$3.77 $14.33

Current Analyst target

+202.44% upside potential · 9 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00HZ0NJ24

ISINCA23256X4075

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.15% ARGX.BR argenx SE +2.09% ARGX argenx SE +2.71% INSM Insmed Inc +0.40% 2269.HK WuXi Biologics (Cayman) Inc -2.78%

Company Profile

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.